MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Search

Avita Therapeutics Inc

Geschlossen

3.42 -0.58

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

3.39

Max

3.45

Schlüsselkennzahlen

By Trading Economics

Einkommen

-3.3M

-13M

Verkäufe

-1.4M

17M

Gewinnspanne

-77.289

Angestellte

260

EBITDA

-3.2M

-11M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+23.19% upside

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-16M

105M

Vorheriger Eröffnungskurs

4

Vorheriger Schlusskurs

3.42

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

Avita Therapeutics Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

31. Dez. 2025, 22:20 UTC

Wichtige Markttreiber

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31. Dez. 2025, 17:31 UTC

Wichtige Markttreiber

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31. Dez. 2025, 16:30 UTC

Wichtige Markttreiber

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31. Dez. 2025, 15:19 UTC

Wichtige Markttreiber

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31. Dez. 2025, 15:17 UTC

Wichtige Markttreiber

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31. Dez. 2025, 14:37 UTC

Wichtige Markttreiber

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

31. Dez. 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31. Dez. 2025, 21:13 UTC

Akquisitionen, Fusionen, Übernahmen

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31. Dez. 2025, 20:40 UTC

Market Talk

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31. Dez. 2025, 20:22 UTC

Market Talk

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31. Dez. 2025, 19:50 UTC

Market Talk

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31. Dez. 2025, 19:31 UTC

Market Talk

Precious Metals Cap Off Record Runs -- Market Talk

31. Dez. 2025, 18:50 UTC

Market Talk

Global Equities Roundup: Market Talk

31. Dez. 2025, 18:50 UTC

Market Talk

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31. Dez. 2025, 17:17 UTC

Market Talk

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31. Dez. 2025, 17:16 UTC

Wichtige Markttreiber

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31. Dez. 2025, 17:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

31. Dez. 2025, 17:00 UTC

Akquisitionen, Fusionen, Übernahmen

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31. Dez. 2025, 15:57 UTC

Akquisitionen, Fusionen, Übernahmen

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31. Dez. 2025, 15:54 UTC

Market Talk

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31. Dez. 2025, 15:02 UTC

Wichtige Markttreiber

Nike Shares Rise After CEO Hill Buys $1M of Shares

31. Dez. 2025, 14:40 UTC

Akquisitionen, Fusionen, Übernahmen

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31. Dez. 2025, 14:20 UTC

Market Talk

Crude Futures On Track to End the Year With Losses -- Market Talk

31. Dez. 2025, 13:46 UTC

Market Talk

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

31. Dez. 2025, 13:01 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Charles Schwab Is Back on Offense. Its Stock Is a Buy. -- Barrons.com

31. Dez. 2025, 11:10 UTC

Market Talk

Copper Remains in Touching Distance of Record Highs -- Market Talk

31. Dez. 2025, 10:46 UTC

Market Talk

Euro on Track For Strong Annual Performance -- Market Talk

31. Dez. 2025, 10:25 UTC

Market Talk

European Gas Prices Rise But Remain on Track for Heavy Annual Loss -- Market Talk

31. Dez. 2025, 10:23 UTC

Market Talk

Chinese Yuan Rises to 31-Month High Against Dollar as Policymakers -- Market Talk

31. Dez. 2025, 09:33 UTC

Market Talk

Dollar Set For Worst Annual Performance Since 2017 -- Market Talk

Peer-Vergleich

Kursveränderung

Avita Therapeutics Inc Prognose

Kursziel

By TipRanks

23.19% Vorteil

12-Monats-Prognose

Durchschnitt 4.25 USD  23.19%

Hoch 5.5 USD

Tief 3 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Avita Therapeutics Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

3 ratings

1

Buy

2

Halten

0

Sell

Technischer Score

By Trading Central

8.83 / 9.77Unterstützung & Widerstand

Kurzfristig

Very Strong Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Weak Bearish Evidence

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.
help-icon Live chat